Rigel Pharmaceuticals | RIGL - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Agenus USD 16.02M 2.85M 2025-12
Amgen USD 653M 32M 2025-12
Anika Therapeutics 189.44M 1.76M 2025-09
Arrowhead Research USD 22.5M 811K 2025-12
AstraZeneca USD 484M 181M 2025-12
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Daiichi Sankyo JPY 2.16B 1.33B 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Halozyme Therapeutics USD 4.91M 615K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Intrexon USD 2K 5K 2024-06
Ionis Pharmaceuticals USD 18M 0 2025-12
Karyopharm Therapeutics USD 11.38M 2.43M 2024-09
Ligand Pharmaceuticals USD 910K 243K 2025-09
MacroGenics USD 3.34M 2.54M 2025-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 711M 59M 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Veracyte USD 2K 1000 2023-12